Hemab Therapeutics (NASDAQ:COAG) Director Ra Capital Management, L.P. Acquires 68,018 Shares

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Director Ra Capital Management, L.P. bought 68,018 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were bought at an average cost of $24.60 per share, for a total transaction of $1,673,242.80. Following the completion of the acquisition, the director directly owned 6,314,525 shares in the company, valued at approximately $155,337,315. This trade represents a 1.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The stock was bought at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were bought at an average price of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Up 0.0%

Shares of Hemab Therapeutics stock traded up $0.01 during midday trading on Wednesday, reaching $25.01. The company had a trading volume of 569,606 shares, compared to its average volume of 536,569. Hemab Therapeutics Holdings, Inc. has a fifty-two week low of $23.48 and a fifty-two week high of $36.61.